A Review of Treatment Methods and Available Therapies for Individuals with ADHD
DOI:
https://doi.org/10.12775/QS.2025.37.57072Keywords
attention deficit hyperactivity disorders (ADHD), neurodevelopmental disorder, pharmacological treatment, stimulants, non-stimulants, cognitive behavioral therapy (CBT),, psychosocial interventions, functional impairmentsAbstract
This review explores treatment approaches and therapies for Attention Deficit Hyperactivity Disorder (ADHD), a neurodevelopmental condition affecting adults, with symptoms often persisting from childhood into adulthood. The research examines the efficacy, tolerability, and accessibility of pharmacological and psychosocial interventions. ADHD management necessitates a multimodal approach combining medications, behavioral therapies, and educational interventions tailored to individual needs.
The analysis focuses on stimulant and non-stimulant medications, including methylphenidate, amphetamines, atomoxetine, and alpha-2 agonists, with regional variations in treatment guidelines. Stimulants, primarily methylphenidate and amphetamine formulations, demonstrate robust efficacy in symptom reduction for patients. Non-stimulant options like atomoxetine are recommended for patients with contraindications to stimulants. Emerging formulations, such as extended-release medications, address tolerance and adherence challenges.
Psychosocial interventions, particularly cognitive behavioral therapy (CBT), complement pharmacological treatments by targeting organizational skills, emotional regulation, and comorbidities like anxiety and depression. Evidence suggests that combined approaches improve long-term functional outcomes, such as academic performance and interpersonal relationships.
Despite advances, gaps in treatment access and the need for individualized care remain significant challenges. This review underscores the importance of ongoing research to optimize ADHD management strategies and ensure equitable access to effective therapies worldwide.
References
Hesson J, Fowler K. Prevalence and Correlates of Self-Reported ADD/ADHD in a Large National Sample of Canadian Adults. J Atten Disord. 2015; 22(2):191–200. https://doi.org/10.1177/1087054715573992 PMID: 25749874
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Canadian ADHD Practice Guidelines 2011. 1–148 p.
Quintero J, Morales I, Vera R, Zuluaga P, Fernandez A. The Impact of Adult ADHD in the Quality of Life Profile. J Atten Disord. 2017:108705471773304-. https://doi.org/10.1177/1087054717733046
Morkem R, Patten S, Queenan J, Barber D. Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care. J Atten Disord. 2017. https://doi.org/10.1177/1087054717720719
Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficyt hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England). 2014; 28(3):179–203. Epub 2014/02/15. https://doi.org/10.1177/0269881113519509 PMID: 24526134.
Canadian ADHD Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines. Toronto, Ontario: CADDRA, 2018
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM-5TM. Washington, DC: American Psychiatric Publishing; 2013
Willcutt EG, Nigg JT, Pennington BF, et al. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol 2012;121(04):991–1010
Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150 (06):885–890
World Health Organization. ICD-11: International Classification of Diseases 11th Revision. The global standard for diagnostic health information, Geneva: World Health Organization; 2024
Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-462. doi: 10.1016/S0140-6736(19)33004-1. Epub 2020 Jan 23. PMID: 31982036; PMCID: PMC7880081.
Wright N, Moldavsky M, Schneider J, et al. Practitioner review: pathways to care for ADHD — a systematic review of barriers and facilitators. J Child Psychol Psychiatry 2015; 56: 598–617.
Pliszka SR, Bernet W, Bukstein O et al. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit-hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. doi: 10.1097/chi.0b013e318054e724. for the American Academy of Child and Adolescent Psychiatry Work Group on Quality Issues.
Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines, 4th edn. Toronto, ON: Canadian ADHD Resource Alliance, 2018.
Palacio JD, De la Peña-Olvera F, Palacios-Cruz L, Ortiz-León S. Algoritmo latinoamericano de tratamiento multimodal del trastorno por déficit de atención e hiperactividad (TDAH) a través de la vida. Revista Colombiana de Psiquiatria 2009; 38: 35–65.
NICE. Attention deficit hyperactivity disorder: diagnosis and management. March, 2018. https://www.nice.org.uk/guidance/ng87 (accessed Dec 23, 2019).
Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 642-57
Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.
Posner J, Greenhill LL. Attention-deficit/hyperactivity disorder. In: McVoy M, Findling RL, eds. Clinical manual of child and adolescent psychopharmacology, 2nd edn. Arlington, VA: American Psychiatric Association, 2013.
Walitza S, Romanos M, Greenhill LL, Banaschewski T. Attention-Deficit/Hyperactivity Disorders. In: Gerlach M, Warnke A, Greenhill LL, eds. Psychiatric Drugs in Children and Adolescents. Wien: Springer; 2014:369–381
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review andnetwork meta-analysis. Lancet Psychiatry 2018; 5: 727–38.
Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011; 25: 157–69.
Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19: 353–64.
Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165: 1475–88.
Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1284–93.
Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003;23(10):1281–1299. doi: 10.1592/phco.23.12.1281.32697.
Pelham WE, Aronoff HR, Midlam JK et al. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999;103:1–14. doi: 10.1542/peds.103.4.e43.
Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother. 2007;7(2):195–201. doi: 10.1586/14737175.7.2.195.
Straterra [product information] Indianapolis, IN: Lilly USA LLC; April 2015. http://pi.lilly.com/us/strattera-pi.pdf. Accessed March 31, 2016.
Banaschewski T, Roessner V, Dittmann RW et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13:102–116. doi: 10.1007/s00787-004-1010-x.
Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58:99–120. doi: 10.1016/j.pcl.2010.10.009.
Martinez-Raga J, Knect C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27:15–30. doi: 10.1007/s40263-012-0019-9.
Spencer TJ, Kratochvil CJ, Sangal RB et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to 5 years of treatment. J Child Adolesc Psychopharmacol. 2007;17(5):689–699. doi: 10.1089/cap.2006.0100.
Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol. 1990;1(1):87–102. doi: 10.1089/cap.1990.1.87.
Intuniv [product information] Wayne, PA: Shire US Inc; February 2013. http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf. Accessed January 31, 2016.
Kapvay [product information] Florham Park, NJ: Shiongi Inc; February 2013. http://kapvay.com/pdf/kapvay-conc-v1-USPI.pdf. Accessed July 9, 2015.
Molina BSG, Hinshaw SP, Swanson JM et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484–500. doi: 10.1097/CHI.0b013e31819c23d0.
Pelham WE, Fabiano GA. Evidence-based psychosocial treatments for attention deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2008;37(1):184–214. doi: 10.1080/15374410701818681.
Creating a daily report card from home; 2002. How to establish a daily report card (school-home note); cited 2013 April 24 [treatment materials] New York: University of Buffalo Center for Children and Families; http://ccf.buffalo.edu/resources_downloads.php#PT. Accessed May 19, 2016.
Coelho, L.F., Barbosa, D.L.F., Rizzutti, S. et al. Group cognitive behavioral therapy for children and adolescents with ADHD. Psicol. Refl. Crít. 30, 11 (2018). https://doi.org/10.1186/s41155-017-0063-y
Philipsen A. Psychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research. Expert Rev Neurother 2012; 12: 1217–25.
Young S, Amarasinghe JM. Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry 2010; 51: 116–33.
Philipsen A, Jans T, Graf E, et al, and the Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72: 1199–210.
NICE. Attention Deficit Hyperactivity Disorder: The NICE guideline on diagnosis and managment of ADHD in children, young people and adults: The British Psychological Society and The Royal College of Psychiatrists; 2008.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zuzanna Gałuszka, Natalie Papachristoforou , Daria Michałka, Monika Makar , Tomasz Bartuś , Żaneta Góra, Emilia Bąk, Justyna Głowacka , Aleksandra Kocjan , Radosław Chmiel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 7
Number of citations: 0